[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202191378A1 - Активные сложноэфирные производные тестостерона, их композиции и применения - Google Patents

Активные сложноэфирные производные тестостерона, их композиции и применения

Info

Publication number
EA202191378A1
EA202191378A1 EA202191378A EA202191378A EA202191378A1 EA 202191378 A1 EA202191378 A1 EA 202191378A1 EA 202191378 A EA202191378 A EA 202191378A EA 202191378 A EA202191378 A EA 202191378A EA 202191378 A1 EA202191378 A1 EA 202191378A1
Authority
EA
Eurasian Patent Office
Prior art keywords
testosterone
new
compositions
applications
active ester
Prior art date
Application number
EA202191378A
Other languages
English (en)
Inventor
Натан Брайсон
Авинаш Чандер Шарма
Original Assignee
Ацерус Биофарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацерус Биофарма Инк. filed Critical Ацерус Биофарма Инк.
Publication of EA202191378A1 publication Critical patent/EA202191378A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к новым соединениям и композициям, содержащим производные активного ингредиента тестостерона и новые производные тестостерона, новым способам тестостерона, новым композициям тестостерона, новым тестостероновым изделиям для получения фармацевтических препаратов и новым терапевтическим применениям тестостерона.
EA202191378A 2018-12-14 2019-12-12 Активные сложноэфирные производные тестостерона, их композиции и применения EA202191378A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779854P 2018-12-14 2018-12-14
PCT/CA2019/051793 WO2020118437A1 (en) 2018-12-14 2019-12-12 Active ester derivatives of testosterone, compositions and uses thereof

Publications (1)

Publication Number Publication Date
EA202191378A1 true EA202191378A1 (ru) 2021-10-04

Family

ID=71072219

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191378A EA202191378A1 (ru) 2018-12-14 2019-12-12 Активные сложноэфирные производные тестостерона, их композиции и применения

Country Status (15)

Country Link
US (1) US20200188412A1 (ru)
EP (1) EP3893885A4 (ru)
JP (1) JP2022517724A (ru)
KR (1) KR20210131305A (ru)
CN (1) CN113365635A (ru)
AU (1) AU2019396139A1 (ru)
BR (1) BR112021011525A2 (ru)
CA (1) CA3123301A1 (ru)
CO (1) CO2021008962A2 (ru)
EA (1) EA202191378A1 (ru)
IL (1) IL283964A (ru)
MX (1) MX2021007032A (ru)
SG (1) SG11202106306YA (ru)
WO (1) WO2020118437A1 (ru)
ZA (1) ZA202104050B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736159A (zh) 2012-08-21 2015-06-24 萨奇治疗股份有限公司 治疗癫痫或癫痫持续状态的方法
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
TWI798173B (zh) 2016-03-08 2023-04-11 美商賽吉醫療公司 神經活性類固醇，其組合物及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
EP1530965B1 (en) * 2003-11-11 2006-03-08 Mattern, Udo Controlled release delivery system of sexual hormones for nasal application
WO2005089670A1 (en) * 2004-03-15 2005-09-29 Durect Corporation Pharmaceutical compositions for administration to a sinus
CN103705462B (zh) * 2010-04-12 2016-08-31 克劳拉斯医疗有限公司 口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
CA3034552C (en) * 2011-05-15 2023-02-07 Acerus Biopharma Inc. Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
WO2014080283A2 (en) * 2012-11-21 2014-05-30 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
WO2014145518A2 (en) * 2013-03-15 2014-09-18 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
KR102514657B1 (ko) * 2014-08-28 2023-03-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 테스토스테론의 제형 및 이를 이용한 치료 방법
SG11201707068XA (en) * 2015-03-02 2017-09-28 Medlab Clinical U S Inc Transmucosal and transdermal delivery systems
WO2017151911A1 (en) * 2016-03-02 2017-09-08 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
WO2017208072A2 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions

Also Published As

Publication number Publication date
KR20210131305A (ko) 2021-11-02
ZA202104050B (en) 2022-04-28
US20200188412A1 (en) 2020-06-18
BR112021011525A2 (pt) 2021-08-31
EP3893885A1 (en) 2021-10-20
EP3893885A4 (en) 2022-09-07
MX2021007032A (es) 2021-10-22
JP2022517724A (ja) 2022-03-10
AU2019396139A1 (en) 2021-07-15
SG11202106306YA (en) 2021-07-29
CN113365635A (zh) 2021-09-07
CA3123301A1 (en) 2020-06-18
WO2020118437A1 (en) 2020-06-18
CO2021008962A2 (es) 2021-10-29
IL283964A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
EA202090573A1 (ru) Составы нирапариба
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
EA201892539A1 (ru) Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
EA202091471A1 (ru) Полиморфы
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
CL2017002229A1 (es) Inhibidores de bace1.
ZA202005083B (en) Solid forms of fasoracetam
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина